Co Diagnostics Financial Statements From 2010 to 2022

CODX
 Stock
  

USD 6.52  0.49  6.99%   

Co Diagnostics financial statements provide useful quarterly and yearly information to potential Co-Diagnostics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Co Diagnostics financial statements helps investors assess Co Diagnostics' valuation, profitability, and current liquidity needs.
We have found eighty available fundamental measures for Co Diagnostics, which can be analyzed and compared to other ratios and to its peers in the sector. Make sure you validate all of Co Diagnostics latest market performance against the performance between 2010 and 2022 to make sure the company can sustain itself for few more years.
Co Diagnostics Average Assets are fairly stable at the moment as compared to the past year. Co Diagnostics reported Average Assets of 109.83 Million in 2021. Earnings Before Interest Taxes and Depreciation Amortization EBITDA is likely to rise to about 49.6 M in 2022, whereas Enterprise Value is likely to drop slightly above 147.5 M in 2022.
  
Check Co Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Co Diagnostics main balance sheet or income statement drivers, such as Consolidated Income of 39.6 M, Cost of Revenue of 9.4 M or Earning Before Interest and Taxes EBIT of 49.2 M, as well as many exotic indicators such as Asset Turnover of 0.76, Book Value per Share of 5.02 or Current Ratio of 8.0. Co Diagnostics financial statements analysis is a perfect complement when working with Co Diagnostics Valuation or Volatility modules. It can also supplement Co Diagnostics' financial leverage analysis and stock options assessment as well as various Co Diagnostics Technical models . Continue to the analysis of Co Diagnostics Correlation against competitors.

Co Diagnostics Revenues

105.61 Million

Co Diagnostics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets172.7 M160 M32 M
Increasing
Slightly volatile
Cash and Equivalents95.6 M88.6 M18 M
Increasing
Slightly volatile
Investments2.4 M2.4 M936.9 K
Increasing
Slightly volatile
Investments Current1.9 M1.3 M3.9 M
Decreasing
Slightly volatile
Investments Non CurrentM1.1 M396.7 K
Increasing
Slightly volatile
Deferred Revenue173.2 K150 K168.1 K
Decreasing
Stable
Property Plant and Equipment Net2.1 M1.9 M480.8 K
Increasing
Slightly volatile
Inventory2.2 MM963.5 K
Increasing
Slightly volatile
Tax Assets489.6 K492.5 K538.6 K
Decreasing
Slightly volatile
Trade and Non Trade Receivables22.5 M20.8 M4.3 M
Increasing
Slightly volatile
Trade and Non Trade Payables655.5 K607.5 K218.9 K
Increasing
Slightly volatile
Goodwill and Intangible Assets37.5 M37.7 M41.2 M
Decreasing
Slightly volatile
Total Liabilities27.6 M25.6 M5.8 M
Increasing
Slightly volatile
Shareholders Equity145.1 M134.5 M26.2 M
Increasing
Slightly volatile
Accumulated Retained Earnings Deficit58.4 M54.2 M3.6 M
Increasing
Slightly volatile
Current Assets124.2 M115.1 M24.3 M
Increasing
Slightly volatile
Assets Non Current48.5 M44.9 M7.7 M
Increasing
Slightly volatile
Current Liabilities13.6 M12.6 M3.3 M
Increasing
Slightly volatile
Liabilities Non Current14 M13 M2.4 M
Increasing
Slightly volatile
Tax Liabilities2.9 M3.3 MM
Increasing
Slightly volatile
Total Debt2.4 M2.2 M1.7 M
Increasing
Slightly volatile
Debt Current2.2 M2.2 M1.4 M
Increasing
Slightly volatile
Debt Non Current414.7 K400.5 K475.5 K
Decreasing
Slightly volatile
Shareholders Equity USD145.1 M134.5 M26.2 M
Increasing
Slightly volatile
Cash and Equivalents USD95.6 M88.6 M18 M
Increasing
Slightly volatile
Total Debt USD2.4 M2.2 M1.7 M
Increasing
Slightly volatile

Co Diagnostics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues105.6 M97.9 M21.4 M
Increasing
Slightly volatile
Cost of Revenue9.4 M11.6 M2.9 M
Increasing
Slightly volatile
Selling General and Administrative Expense26.9 M24.9 M6.6 M
Increasing
Slightly volatile
Research and Development Expense16.1 M15 M3.4 M
Increasing
Slightly volatile
Operating Expenses43.4 M40.2 M10 M
Increasing
Slightly volatile
Interest Expense123.5 K95.8 K120.7 K
Increasing
Stable
Income Tax Expense7.3 MM1.3 M
Increasing
Slightly volatile
Consolidated Income39.6 M36.7 M6.5 M
Increasing
Slightly volatile
Net Income39.6 M36.7 M6.5 M
Increasing
Slightly volatile
Net Income Common Stock39.6 M36.7 M6.5 M
Increasing
Slightly volatile
Weighted Average Shares24.7 M28.9 M14.4 M
Increasing
Slightly volatile
Weighted Average Shares Diluted25.4 M29.9 M14.6 M
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT49.2 M45.6 M8.1 M
Increasing
Slightly volatile
Revenues USD105.6 M97.9 M21.4 M
Increasing
Slightly volatile
Net Income Common Stock USD39.6 M36.7 M6.5 M
Increasing
Slightly volatile
Earning Before Interest and Taxes USD49.2 M45.6 M8.1 M
Increasing
Slightly volatile
Gross Profit93.1 M86.3 M18.3 M
Increasing
Slightly volatile
Operating Income49.7 M46.1 M8.3 M
Increasing
Slightly volatile

Co Diagnostics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Cash Flow Business Acquisitions and Disposals1.8 M1.7 M127.2 K
Increasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals3.3 M3.1 M(1.2 M)
Decreasing
Very volatile
Net Cash Flow from Financing462.3 K450.4 K3.5 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities M2.3 M1.4 M
Increasing
Slightly volatile
Issuance Purchase of Equity Shares462.3 K450.4 K3.4 M
Increasing
Slightly volatile
Net Cash Flow from Investing4.4 M4.1 M78.3 K
Increasing
Stable
Net Cash Flow from Operations44.3 M41.1 M6.9 M
Increasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents49.2 M45.6 M10.5 M
Increasing
Slightly volatile
Share Based Compensation5.9 M5.5 M1.5 M
Increasing
Slightly volatile
Depreciation Amortization and Accretion361.8 K335.4 K99.6 K
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share1.371.270.093
Increasing
Slightly volatile
Earnings per Diluted Share1.331.230.0813
Increasing
Slightly volatile
Earnings per Basic Share USD1.371.270.093
Increasing
Slightly volatile
Return on Average Equity0.40.368(1.4099)
Decreasing
Stable
Return on Average Assets0.360.334(1.6126)
Increasing
Slightly volatile
Return on Invested Capital2.722.524(13.8672)
Increasing
Slightly volatile
Gross Margin0.810.8820.8946
Decreasing
Slightly volatile
Profit Margin0.40.375(22.0656)
Increasing
Slightly volatile
EBITDA Margin0.510.47(21.4332)
Increasing
Slightly volatile
Return on Sales0.50.466(238)
Increasing
Stable
Asset Turnover0.760.8910.2581
Increasing
Slightly volatile
Enterprise Value over EBITDA4.123.815(1.9503)
Increasing
Slightly volatile
Enterprise Value over EBIT4.324.0(1.7449)
Increasing
Slightly volatile
Price to Earnings Ratio7.587.031(1.4196)
Increasing
Slightly volatile
Sales per Share3.663.390.7586
Increasing
Slightly volatile
Price to Sales Ratio2.72.6342.4 K
Decreasing
Slightly volatile
Price to Book Value1.591.9195.0449
Decreasing
Slightly volatile
Debt to Equity Ratio0.210.19(0.8376)
Increasing
Slightly volatile
Current Ratio8.09.1383.6482
Increasing
Slightly volatile
Free Cash Flow per Share1.511.40.1365
Increasing
Slightly volatile
Book Value per Share5.024.6570.8851
Increasing
Slightly volatile
Tangible Assets Book Value per Share4.424.0910.9404
Increasing
Slightly volatile

Co Diagnostics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings before Tax49.2 M45.6 MM
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA49.6 M46 M8.2 M
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD49.6 M46 M8.2 M
Increasing
Slightly volatile
Market Capitalization203.9 M258 M78.4 M
Increasing
Slightly volatile
Enterprise Value147.5 M175.4 M63 M
Increasing
Slightly volatile
Invested Capital18.3 M16.9 M4.8 M
Increasing
Slightly volatile
Average Equity107.4 M99.5 M18.5 M
Increasing
Slightly volatile
Average Assets118.5 M109.8 M22.3 M
Increasing
Slightly volatile
Invested Capital Average19.5 M18.1 M4.5 M
Increasing
Slightly volatile
Tangible Asset Value127.5 M118.1 M25.3 M
Increasing
Slightly volatile
Free Cash Flow43.6 M40.4 M6.7 M
Increasing
Slightly volatile
Working Capital110.6 M102.5 M21 M
Increasing
Slightly volatile

Co Diagnostics Fundamental Market Drivers

Forward Price Earnings10.97
Short Percent Of Float5.12%
Average Daily Volume Last 10 Day1.16M
Shares Short Prior Month1.85M
Average Daily Volume In Three Month534.92k
Date Short Interest15th of July 2022
Fifty Day Average5.65
Two Hundred Day Average6.73

Co Diagnostics Upcoming Events

Upcoming Quarterly Report24th of March 2022
Next Financial Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About Co Diagnostics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Co Diagnostics income statement, its balance sheet, and the statement of cash flows. Co Diagnostics investors use historical funamental indicators, such as Co Diagnostics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Co Diagnostics investors may use each financial statement separately, they are all related. The changes in Co Diagnostics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Co Diagnostics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Co Diagnostics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Co Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue150 K173.2 K
Cost of Revenue11.6 M9.4 M
Revenues97.9 M105.6 M
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection andor analysis of nucleic acid molecules in the United States and internationally. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Co Diagnostics operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 101 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Co Diagnostics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Pair Trading with Co Diagnostics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Co Diagnostics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Co Diagnostics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Co Diagnostics

0.81AXDXAccelerate Diagnosti Earnings Call  This WeekPairCorr

Moving against Co Diagnostics

0.85AIMAim Immunotech Earnings Call  TomorrowPairCorr
0.84AGRXAgile Therapeutics Earnings Call  This WeekPairCorr
0.75ABCAmerisourcebergen Corp Upward RallyPairCorr
0.75ACHVAchieve Life Sciences Earnings Call  This WeekPairCorr
The ability to find closely correlated positions to Co Diagnostics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Co Diagnostics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Co Diagnostics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Co-Diagnostics to buy it.
The correlation of Co Diagnostics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Co Diagnostics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Co-Diagnostics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Co Diagnostics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Co Diagnostics Correlation against competitors. Note that the Co-Diagnostics information on this page should be used as a complementary analysis to other Co Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Co Diagnostics Stock analysis

When running Co-Diagnostics price analysis, check to measure Co Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Co Diagnostics is operating at the current time. Most of Co Diagnostics' value examination focuses on studying past and present price action to predict the probability of Co Diagnostics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Co Diagnostics' price. Additionally, you may evaluate how the addition of Co Diagnostics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Is Co Diagnostics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Co Diagnostics. If investors know Co Diagnostics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Co Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.31
Market Capitalization
229.7 M
Quarterly Revenue Growth YOY
0.13
Return On Assets
0.23
Return On Equity
0.36
The market value of Co-Diagnostics is measured differently than its book value, which is the value of Co Diagnostics that is recorded on the company's balance sheet. Investors also form their own opinion of Co Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Co Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Co Diagnostics' market value can be influenced by many factors that don't directly affect Co Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Co Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine Co Diagnostics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Co Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.